Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Adicet Bio Inc (ACET)

Adicet Bio Inc (ACET)
0.9734 -0.0266 (-2.66%) 02/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 0.9657 -0.0077 (-) 02/21/25
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9655
Day High
1.0300
Open 1.0200
Previous Close 1.0000 1.0000
Volume 302,800 302,800
Avg Vol 1,568,690 1,568,690
Stochastic %K 62.03% 62.03%
Weighted Alpha -56.81 -56.81
5-Day Change +0.0739 (+8.22%) +0.0739 (+8.22%)
52-Week Range 0.8100 - 2.7400 0.8100 - 2.7400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,209
  • Shares Outstanding, K 82,401
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,660 K
  • EBIT $ -128 M
  • EBITDA $ -103 M
  • 60-Month Beta 1.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.39
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.71
  • Most Recent Earnings $-0.34 on 11/06/24
  • Next Earnings Date 03/18/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 439.50% ( +178.94%)
  • Historical Volatility 61.66%
  • IV Percentile 90%
  • IV Rank 64.45%
  • IV High 677.57% on 01/17/25
  • IV Low 7.83% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,510
  • Open Int (30-Day) 1,056

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.37
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.38
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +46.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8384 +16.10%
on 02/12/25
Period Open: 0.9389
1.0900 -10.70%
on 02/06/25
+0.0345 (+3.67%)
since 01/21/25
3-Month
0.8100 +20.17%
on 12/19/24
Period Open: 0.9140
1.1900 -18.20%
on 12/02/24
+0.0594 (+6.50%)
since 11/21/24
52-Week
0.8100 +20.17%
on 12/19/24
Period Open: 2.6900
2.7400 -64.47%
on 02/22/24
-1.7166 (-63.81%)
since 02/21/24

Most Recent Stories

More News
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

KURA : 8.25 (+1.23%)
SHPH : 0.6170 (+3.70%)
LPTX : 0.4802 (-0.52%)
NXTC : 0.7229 (-3.74%)
ACET : 0.9734 (-2.66%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April...

ACET : 0.9734 (-2.66%)
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 0.9734 (-2.66%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March...

ACET : 0.9734 (-2.66%)
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights...

ACET : 0.9734 (-2.66%)
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 0.9734 (-2.66%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on February...

ACET : 0.9734 (-2.66%)
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 0.9734 (-2.66%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January...

ACET : 0.9734 (-2.66%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on December...

ACET : 0.9734 (-2.66%)

Business Summary

Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

See More

Key Turning Points

3rd Resistance Point 1.0783
2nd Resistance Point 1.0541
1st Resistance Point 1.0138
Last Price 0.9734
1st Support Level 0.9493
2nd Support Level 0.9251
3rd Support Level 0.8848

See More

52-Week High 2.7400
Fibonacci 61.8% 2.0027
Fibonacci 50% 1.7750
Fibonacci 38.2% 1.5473
Last Price 0.9734
52-Week Low 0.8100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements